MA29398B1 - Derives de coumarine substituee par un thiadiazole et leur utilisation en tant qu'inhibiteur de biosynthese de leucotriene. - Google Patents

Derives de coumarine substituee par un thiadiazole et leur utilisation en tant qu'inhibiteur de biosynthese de leucotriene.

Info

Publication number
MA29398B1
MA29398B1 MA30306A MA30306A MA29398B1 MA 29398 B1 MA29398 B1 MA 29398B1 MA 30306 A MA30306 A MA 30306A MA 30306 A MA30306 A MA 30306A MA 29398 B1 MA29398 B1 MA 29398B1
Authority
MA
Morocco
Prior art keywords
biosynthesis inhibitors
coumarin derivatives
substituted coumarin
aromatic core
thiadiazole substituted
Prior art date
Application number
MA30306A
Other languages
English (en)
Inventor
Marc Blouin
Erich L Grimm
Yves Gareau
Marc Gagnon
Helene Juteau
Sebastien Laliberte
Bruce Mackay
Richard Friesen
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37023348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29398(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of MA29398B1 publication Critical patent/MA29398B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS RÉPONDANT À LA FORMULE (IA) QUI SONT DES INHIBITEURS DE BIOSYNTHÈSE DE LEUCOTRIÈNE, DANS LAQUELLE X REPRÉSENTE O OU S, Y REPRÉSENTE O, S, -NR6-CHR7- OU -NR8-C(O)- ET A EST CHOISI PARMI UN NOYAU AROMATIQUE HÉTÉROCYCLIQUE À 5 CHAÎNONS, UN NOYAU AROMATIQUE HÉTÉROCYCLIQUE À 6 CHAÎNONS, UN SYSTÈME DE NOYAU AROMATIQUE NAPHTALÉNIQUE OU HÉTÉROBICYCLIQUE, UN GROUPE PHÉNYLE ET UN GROUPE BENZYLE. A EST ÉVENTUELLEMENT MONO- OU DISUBSTITUÉ. LES COMPOSÉS RÉPONDANT À LA FORMULE (IA) SONT UTILES EN TANT QU¿AGENTS ANTI-ATHÉROSCLÉROTIQUE, ANTI-ASTHMATIQUE, ANTI-ALLERGIQUE, ANTI-INFLAMMATOIRE ET CYTOPROTECTEUR.
MA30306A 2005-03-23 2007-10-17 Derives de coumarine substituee par un thiadiazole et leur utilisation en tant qu'inhibiteur de biosynthese de leucotriene. MA29398B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66431705P 2005-03-23 2005-03-23

Publications (1)

Publication Number Publication Date
MA29398B1 true MA29398B1 (fr) 2008-04-01

Family

ID=37023348

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30306A MA29398B1 (fr) 2005-03-23 2007-10-17 Derives de coumarine substituee par un thiadiazole et leur utilisation en tant qu'inhibiteur de biosynthese de leucotriene.

Country Status (26)

Country Link
US (3) US7553973B2 (fr)
EP (1) EP1869031B1 (fr)
JP (2) JP4109316B1 (fr)
KR (1) KR20070113259A (fr)
CN (2) CN101146802A (fr)
AR (1) AR055041A1 (fr)
AU (1) AU2006227524B2 (fr)
BR (1) BRPI0609687A2 (fr)
CA (1) CA2600727C (fr)
CR (1) CR9442A (fr)
DO (1) DOP2006000069A (fr)
EA (1) EA012704B1 (fr)
ES (1) ES2394179T3 (fr)
GT (1) GT200600117A (fr)
IL (1) IL185724A0 (fr)
MA (1) MA29398B1 (fr)
MX (1) MX2007011638A (fr)
MY (1) MY142105A (fr)
NI (1) NI200700242A (fr)
NO (1) NO20075384L (fr)
PA (1) PA8667201A1 (fr)
PE (1) PE20061328A1 (fr)
TN (1) TNSN07348A1 (fr)
TW (1) TWI321130B (fr)
WO (1) WO2006099735A1 (fr)
ZA (1) ZA200707385B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR055041A1 (es) * 2005-03-23 2007-08-01 Merck Frosst Canada Ltd Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
JP2009510132A (ja) * 2005-10-05 2009-03-12 メルク フロスト カナダ リミテツド ロイコトリエン生合成の阻害剤としての置換キノリン
AR065093A1 (es) * 2007-02-05 2009-05-13 Merck Frosst Canada Ltd Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
AR068498A1 (es) * 2007-09-27 2009-11-18 Merck & Co Inc Compuestos de oxadiazol para inhibicion de biosintesis de leucotrienos
JP2013501064A (ja) 2009-08-04 2013-01-10 アミラ ファーマシューティカルス，インコーポレーテッド リゾホスファチジン酸受容体アンタゴニストとしての化合物
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
WO2012078593A2 (fr) 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
CN107721940A (zh) 2010-12-07 2018-02-23 阿米拉制药公司 多环lpa1拮抗剂及其使用
CN103596947A (zh) 2011-04-05 2014-02-19 艾米拉医药股份有限公司 用于治疗纤维化、疼痛、癌症和呼吸、过敏性、神经系统疾病或心血管疾病的基于3-或5-联苯-4-基异噁唑的化合物
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
WO2014031586A2 (fr) * 2012-08-20 2014-02-27 Tallikut Pharmaceuticals, Inc. Procédés permettant de traiter des maladies cardiovasculaires
CN102924442B (zh) * 2012-11-15 2014-10-29 沈阳药科大学 含有噻唑环的色满类化合物及其类似物和医药用途
CN103304556B (zh) * 2013-06-21 2016-06-01 天津药物研究院有限公司 含有苯并吡喃的希夫碱类化合物、其制备方法和用途
MX376835B (es) 2015-03-06 2025-03-07 Pharmakea Inc Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
EP3354648B1 (fr) * 2015-09-24 2022-04-06 Chengdu Zenitar Biomedical Technology Co., Ltd. Dérivé de coumarine 4-substitué, son procédé de préparation et d'utilisation
SG11201901999XA (en) 2016-09-07 2019-04-29 Pharmakea Inc Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
KR20230162996A (ko) 2016-09-07 2023-11-29 파마케아, 인크. 리실 옥시다제 유사 2 억제제의 용도
CN108658962B (zh) * 2017-03-30 2021-10-01 复旦大学 3-取代香豆素呋咱衍生物及其在制备抗多药耐药肿瘤药物中的用途
CN111116506B (zh) * 2019-12-31 2024-03-08 浙江大学衢州研究院 一种芳巯基二唑类衍生物的合成方法
CN113149979B (zh) * 2021-03-05 2022-11-25 朗捷睿(苏州)生物科技有限公司 一种8-(苯并噻唑酰胺)取代香豆素类化合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3834860A1 (de) * 1988-10-13 1990-04-19 Basf Ag Heterocyclisch substituierte alkoxycumarine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel
DE4235603A1 (de) 1992-10-22 1994-04-28 Basf Ag Arylalkoxythiocumarine, Verfahren zu ihrer Herstellung und diese enthaltende therapeutische Mittel
US5424320A (en) 1993-06-23 1995-06-13 Merck Frosst Canada, Inc. Heteroaryl coumarins as inhibitors of leukotriene biosynthesis
EP0650964A1 (fr) 1993-11-02 1995-05-03 Duphar International Research B.V Dérivés de 1- 2H-1-benzopyran-2-one-8-yl -pipérazine
US5552437A (en) 1994-10-27 1996-09-03 Merck Frosst Canada, Inc. Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis
US5576338A (en) * 1995-02-15 1996-11-19 Merck Frosst Canada, Inc. Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
US6265421B1 (en) 1997-06-25 2001-07-24 Orion Corporation Phospholamban inhibitors and a method for increasing coronary flow
US6538022B1 (en) 1997-09-24 2003-03-25 Orion Corporation Compounds for deactivating phospholamban function on Ca-ATPase (phopholamban inhibitors)
US5968959A (en) * 1997-12-12 1999-10-19 Orion Corporation Method for the prevention and treatment of stunned myocardium
US6974806B2 (en) * 2000-07-13 2005-12-13 Takeda Pharmaceutical Company Limited Lipid-rich plaque inhibitors
WO2002047723A1 (fr) 2000-12-11 2002-06-20 Takeda Chemical Industries, Ltd. Compositions medicamenteuses presentant une meilleure hydrosolubilite
AU2003249534A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
JP2006527207A (ja) * 2003-06-11 2006-11-30 メルク フロスト カナダ リミテツド ７−（１，３−チアゾール−２−イル）チオ−クマリン誘導体およびそれのロイコトリエン生合成阻害薬としての使用
AR055041A1 (es) * 2005-03-23 2007-08-01 Merck Frosst Canada Ltd Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.

Also Published As

Publication number Publication date
PE20061328A1 (es) 2007-01-13
PA8667201A1 (es) 2006-10-13
AU2006227524B2 (en) 2011-06-30
US20090030048A1 (en) 2009-01-29
DOP2006000069A (es) 2006-09-30
EP1869031A1 (fr) 2007-12-26
EP1869031A4 (fr) 2011-02-09
AU2006227524A1 (en) 2006-09-28
TW200700414A (en) 2007-01-01
KR20070113259A (ko) 2007-11-28
CA2600727C (fr) 2011-06-14
JP4109316B1 (ja) 2008-07-02
TWI321130B (en) 2010-03-01
EA200702058A1 (ru) 2008-02-28
MX2007011638A (es) 2007-11-14
NO20075384L (no) 2007-11-30
CA2600727A1 (fr) 2006-09-28
US20090227638A1 (en) 2009-09-10
EP1869031B1 (fr) 2012-08-08
JP5207711B2 (ja) 2013-06-12
ZA200707385B (en) 2010-01-27
WO2006099735A1 (fr) 2006-09-28
TNSN07348A1 (en) 2008-12-31
EA012704B1 (ru) 2009-12-30
JP2008533179A (ja) 2008-08-21
GT200600117A (es) 2007-01-19
US20070149579A1 (en) 2007-06-28
BRPI0609687A2 (pt) 2010-04-20
MY142105A (en) 2010-09-15
JP2008101010A (ja) 2008-05-01
CR9442A (es) 2008-01-21
NI200700242A (es) 2008-05-13
CN101146802A (zh) 2008-03-19
CN102627638A (zh) 2012-08-08
ES2394179T3 (es) 2013-01-23
US7553973B2 (en) 2009-06-30
IL185724A0 (en) 2008-01-06
AR055041A1 (es) 2007-08-01

Similar Documents

Publication Publication Date Title
EP1620411A4 (fr) Inhibiteurs de l'activite de l'akt
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
ATE362932T1 (de) Azaindolverbindungen als kinaseinhibitoren
NO20070526L (no) Kinazolindionderivater som parp-inhibitorer
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
NI200700242A (es) Derivados de cumarina sustituidos con tiadiazol y sus usos como inhibidores de la biosíntesis de leucotrienos.
UY30118A1 (es) Compueto amina trisustituido
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
MA27180A1 (fr) N-aryl-2-oxazolidinone-5-carboxamides et leurs derives, et leur utilisation comme agents antibacteriens
MA27561A1 (fr) Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases
NO20021358D0 (no) Alkylendiamin-substituerte heterocykler
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20083207L (no) Inhibitorer av IAP
NO20074718L (no) BCRP/ABCG2 inhibitor
EA200970124A1 (ru) Производные 2-арилиндола в качестве ингибиторов npges-1
ATE464307T1 (de) Mif-hemmer
ATE355265T1 (de) Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
HRP20080529T3 (en) Amide prodrug of gemcitabine, compositions and use thereof
DE602004014628D1 (de) Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren
DE502005005809D1 (de) Neue aryl-haltige 5-acylindolinone, deren herstellung und deren verwendung als arzneimittel
EA200600601A1 (ru) Производные аминопиридина в качестве ингибиторов индуцируемой no-синтазы
ATE403655T1 (de) Imidazopyridinderivate als induzierbare no- synthaseinhibitoren
ATE399169T1 (de) Imidazopyridinderivate als inhibitoren der induzierbaren no-synthase
ATE425141T1 (de) Neue heteroarylsubstituierte acetonderivate als hemmstoffe der phospholipase a sb 2 /sb
ATE236901T1 (de) Herbizide substituierte thienocycloalk(en)ylamino-1,3,5-triazine